Advertisement

Drugs & Aging

, Volume 35, Issue 11, pp 1005–1015 | Cite as

Medication Exposure and Health Outcomes in Older Patients with End-Stage Kidney Disease: A Prospective Study Undertaken in New Zealand

  • Sashika Samaranayaka
  • Robert J. WalkerEmail author
  • Ari Samaranayaka
  • Sarah Derrett
  • John W. B. Schollum
Original Research Article

Abstract

Background

The impact of multiple medication exposure on health outcomes among older patients with end-stage kidney disease (ESKD) is unknown.

Objective

The objective of this study was to identify the impact of medicine exposure on hospitalisation rates and mortality in a prospective longitudinal observational study of older dialysis patients.

Methods

Patient demographics, medication use, hospitalisation, mortality and co-morbidity data were collected through the prospective longitudinal cohort study DOS65 + (Dialysis Outcomes in those aged ≥ 65 years Study) (n = 225). Medication exposure was measured by the total number of individual medications and the number of predetermined ‘medication groups’. Associations between medications prescribed at recruitment and health outcomes as measured by hospitalisation and mortality were assessed by univariate and multivariable regression analyses.

Results

Older ESKD patients were exposed to a median of ten (0–20) medications and eight (0–15) medication groups. Multivariate analyses estimate each additional medication increased mortality risk by 8% (relative risk [RR] = 1.08; 95% confidence interval [CI] 1.07–1.09); each medication group increased mortality risk by 11% (RR = 1.11; 95% CI 1.09–1.12). Similar trends were observed for hospitalisation. Certain medication groups were associated with reduced hospitalisation rates, namely angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (RR = 0.62; 95% CI 0.53–0.72) and dihydropyridines (RR = 0.64; 95% CI 0.54–0.76). Warfarin, gastric acid suppressants, diuretics and β-blockers were associated with increased hospitalisation rates. Warfarin was associated with an increased mortality rate (RR = 1.40; 95% CI 1.19–1.65).

Conclusions

Multiple medication exposure was prevalent in this older ESKD population, and was associated with an increased risk of mortality and hospitalisation. While this study is not able to determine the cause of these relationships, review of medication use is warranted in this population.

Trial Registration

ACTRN12611000024943.

Notes

Acknowledgements

Sashika Samaranayaka was a recipient of an Otago Medical Research Foundation–Metro Realty summer studentship.

Author Contributions

RW and SD were responsible for the research idea and design; all authors contributed to data analyses and interpretation, manuscript authorship and review; AS and SS were responsible for the statistical analyses. SS was supervised by RW, SD, JS and AS.

Compliance with Ethical Standards

Funding

The DOS65 + (Dialysis Outcomes in those aged ≥ 65 years Study) was funded by the Health Research Council (HRC) of New Zealand (HRC 10/354). The study was investigator-initiated and analysed, with no contribution from the HRC to the analyses.

Conflict of interest

Sashika Samaranayaka, Robert Walker, Ari Samaranayaka, Sarah Derrett and John Schollum declare that they have no conflicts of interest relevant to the content of this study.

Ethical approval

The study was approved by the New Zealand Multi-Regional Ethics Committee (MEC/10/084) and registered in Australian New Zealand clinical trials registry (ACTRN12611000024943).

Supplementary material

40266_2018_582_MOESM1_ESM.xlsx (20 kb)
Supplementary Table 1: Detailed table with the complete data for four multivariable Negative Binomial models showing the effect of medication exposure on risk of hospitalisation after adjusting for confounders. Supplementary Table 2: Detailed table with the complete data for four Modified Poisson models showing the effect of medication exposure on risk of death after adjusting for confounders (XLSX 21 kb)

References

  1. 1.
    Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408–12.CrossRefGoogle Scholar
  2. 2.
    Abe T, Tamiya N, Kitahara T, Tokuda Y. Polypharmacy as a risk factor for hospital admission among ambulance-transported old-old patients. Acute Med Surg. 2016;3:107–13.CrossRefGoogle Scholar
  3. 3.
    Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547–60.CrossRefGoogle Scholar
  4. 4.
    Chang Y-P, Huang S-K, Tao P, Chien C-W. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrol. 2012;13(1):96.CrossRefGoogle Scholar
  5. 5.
    Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure—a register-based study in Sweden 2005–2009. Health Policy. 2013;109(2):166–74.CrossRefGoogle Scholar
  6. 6.
    Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123–32.CrossRefGoogle Scholar
  7. 7.
    Nishtala PS, Bagge ML, Campbell AJ, Tordoff JM. Potentially inappropriate medicines in a cohort of community-dwelling older people in New Zealand. Geriatr Gerontol Int. 2014;14(1):89–93.CrossRefGoogle Scholar
  8. 8.
    Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005–2013. Gerontol. 2014;61(3):195–202.CrossRefGoogle Scholar
  9. 9.
    McIntyre C, McQuillan R, Bell C, Battistella M. Targeted deprescribing in an outpatient hemodialysis unit: a quality improvement study to decrease polypharmacy. Am J Kidney Dis. 2017;70:611–8.CrossRefGoogle Scholar
  10. 10.
    Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatric Med. 2012;28(2):159–72.CrossRefGoogle Scholar
  11. 11.
    Mason NA, Bakus JL, editors. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial. 2010;23:55–61.Google Scholar
  12. 12.
    Flaherty JH, Perry HM, Lynchard GS, Morley JE. Polypharmacy and hospitalisation among older home care patients. J Gerontol A Biol Sci Med Sci. 2000;55(10):M554–9.CrossRefGoogle Scholar
  13. 13.
    Sganga F, Landi F, Ruggiero C, et al. Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study. Geriatr Gerontol Int. 2015;15(2):141–6.CrossRefGoogle Scholar
  14. 14.
    Espino DV, Bazaldua OV, Palmer RF, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE study. J Gerontol A Biol Sci Med Sci. 2006;61(2):170–5.CrossRefGoogle Scholar
  15. 15.
    Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039–48.CrossRefGoogle Scholar
  16. 16.
    Jones SA, Bhandari S. The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgrad Med J. 1051;2013(89):247–50.Google Scholar
  17. 17.
    St Peter WL. Management of polypharmacy in dialysis patients. Semin Dial. 2015;28(4):427–32.CrossRefGoogle Scholar
  18. 18.
    Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80.CrossRefGoogle Scholar
  19. 19.
    Walker R, Derrett S, Campbell J, et al. Dialysis outcomes in those aged ≥ 65 years. BMC Nephrol. 2013;14:175.CrossRefGoogle Scholar
  20. 20.
    Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004;44:7–15.CrossRefGoogle Scholar
  21. 21.
    Ministry of Health. HISO 10001:2017 ethnicity data protocols. Wellington: Ministry of Health; 2017.Google Scholar
  22. 22.
    World Health Organization. Global database on body mass index. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 20 Dec 2017.
  23. 23.
    Reenen MV, Oppe M. EQ-5D-3L user guide. Rotterdam: EuroQol Research Foundation; 2015.Google Scholar
  24. 24.
    Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6.CrossRefGoogle Scholar
  25. 25.
    Statistics New Zealand. Ethnic group (total responses) by age group and sex, for the census usually resident population count, 2001, 2006, and 2013 Censuses. Wellington: Statistics New Zealand; 2013. https://www.stats.govt.nz/topics/census. Accessed 24 Aug 2018.
  26. 26.
    McDonald S, Excell L, Livingston B, editors. ANZDATA Registry report 2010: the Australia and New Zealand Dialysis and Transplant Registry. ANZDATA registry: Adelaide; 2010.Google Scholar
  27. 27.
    Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRefGoogle Scholar
  28. 28.
    Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44:61–7.CrossRefGoogle Scholar
  29. 29.
    Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, INDEPENDENT Study Investigators, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771–8.CrossRefGoogle Scholar
  30. 30.
    Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;5(5):CD008165.Google Scholar
  31. 31.
    Gallagher P, O’Connor M, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–54.CrossRefGoogle Scholar
  32. 32.
    Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med. 2013;18(4):121–4.CrossRefGoogle Scholar
  33. 33.
    Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36(1):26–9.CrossRefGoogle Scholar
  34. 34.
    Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease. A systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263–75.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Medicine, Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand
  2. 2.Department of Preventive and Social Medicine, Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand

Personalised recommendations